Sysmex: Script file ( PDF format / 5.4MB )







Presentation

Ietsugu: Hello. This is Ietsugu. I would first like to say a few words to you on the occasion of this R&D Meeting. This is our 19th R&D meeting.

We created SYSMEX’s long-term management objectives in 2017 and announced them in 2018.

We have only three years left before reaching the goal in 2025. Based on the Sysmex method, which is our business philosophy, we have defined a long-term vision to become a health testing company unique and advanced.

We have established these five positioning points for our future progress. On the other hand, however, since we set these targets in 2017, the situation is changing considerably. In any case, it is very important that we continue to develop with technology at the heart.

Next please. I would like to talk about changes in the external environment.

As you know, Covid‐19 has impacted us for two years, and one of the major changes is that our lifestyles have changed drastically, as they say, with the coronavirus and after the coronavirus.

On the other hand, sustainable management, including the SDGs, will become very important in the future. We are meeting this challenge, but the external environment has changed slightly since the establishment of our long-term management plan, as I mentioned earlier.

On the technical side, PCR has become a common name, and DX, scanning, has become a very important factor, and we are working on it. On the other hand, we are moving towards the goal of becoming carbon neutral.

The healthcare market and market are changing dramatically due to COVID‐19. Traditionally, developed countries have focused on how to reduce medical costs. However, this is no longer the case. Rather, we are aiming for the strengthening of health infrastructures, self-medication, digitalization and, especially in Japan, the start of online medical care, which has lagged behind, and, of course, personalized medicine is progressing.

1

SYSMEX has established a comprehensive R&D structure, beginning with the establishment of an R&D base in 1993 at the Techno Center (currently Technopark), which has been operating for about 30 years and is now expanding overseas.

In particular, we will recently establish RDCAP in Singapore, which means that our global network has just been established. R&D spending is now essentially 7% of sales, and since SYSMEX has always been a technology-driven company, we are certainly focusing on that area.

2

Then there is the creation of value for SYSMEX.

As you can see on the left, our main resources are R&D, manufacturing, production and our global sales and service network. In this context, we have diversified human resources.

In particular, as I have already said, one of our objectives is to make our three technological platforms, cellular measurement, protein measurement and gene measurement, more sensitive. On the other hand, as indicated in our product, service and quality offer, we are able to provide our customers with our own instruments, specialized reagents and software. We are also able to control the quality.

And we are now taking on the challenges of DX, digital transformation, and at the same time we believe that diagnosis, disease management and personalized medicine are very important. We are developing these areas, including liquid biopsy. On the other hand, as you can see, we are also taking up the challenge of medical robotics and regenerative cell medicine as new areas.

Either way, SYSMEX is now focused on solving social problems and achieving sustainable growth. That’s all.

Moderator: Now, Mr. Asano, senior manager, please begin.

Asano: My name is Asano. Thank you very much for participating in our R&D meeting today.

3

During this fiscal year, we launched a new medium-term management plan, and I would like to explain the R&D activities that we have undertaken during the period of this medium-term management plan.

The figure on the left of this slide shows our basic strategy. In the existing inspection field, we will strive for continuous growth by introducing new products. At the same time, in the field of personalized medicine, which we have been engaged in research and development since the past, as explained in the R&D meetings, we have entered the full-fledged commercialization phase and we will continue to promote it. Our core strategy is to use our technological strengths to cultivate new businesses seeking new growth opportunities.

In order to achieve these objectives, this medium-term management plan defines and implements the priority actions indicated on the right side of this slide. The red parts indicate areas related to research and development in particular.

4

This is an excerpt from the original content. To continue reading it, go to the original document here.

Warning

Sysmex Company published this content on March 09, 2022 and is solely responsible for the information contained therein. Distributed by publicunedited and unmodified, on March 09, 2022 06:20:10 UTC.

Public now 2022

All SYSMEX CORPORATION news

2022 sales 359B
3,099 million
3,099 million
Net income 2022 44,935 million
388M
388M
Net cash 2022 65,130M
563M
563M
PER 2022 ratio 40.5x
2022 return 0.86%
Capitalization 1,822B
15,743 million
15,743 million
EV / Sales 2022 4.90x
EV / Sales 2023 4.43x
# of employees 8,445
Floating

Chart SYSMEX CORPORATION


Duration :

Period :




Sysmex Corporation Technical Analysis Chart |  MarketScreener

Trends in Technical Analysis SYSMEX CORPORATION

Short term Middle term Long term
Tendencies Bearish Bearish Bearish



Evolution of the income statement

To sell

To buy

Medium consensus HOLD
Number of analysts 14
Last closing price

¥8,707.00

Average target price

JPY12,600.00

Average Spread / Target 44.7%